InnoCan - Founder and CEO, Iris Bincovich.
Founder and CEO, Iris Bincovich.
Source: The Investor Coliseum.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • InnoCan Pharma’s (INNO) Liposome Platform Technology has achieved a 7-week release of CBD into the bloodstream in a recent animal study
  • The company is encouraged by the result given that CBD only stays in the bloodstream for 24 hours when administered through traditional channels
  • Liposome Platform Technology may have use cases for epilepsy, pain relief, inflammation and central nervous system disorders
  • InnoCan Pharma is a pharmaceutical tech company focused on the development of drug delivery platforms containing CBD
  • InnoCan Pharma (INNO) is trading flat at $0.50 per share

InnoCan Pharma’s (INNO) Liposome Platform Technology has achieved a 7-week release of CBD into the bloodstream in a recent animal study.

The mice in question demonstrated the prolonged release of cannabidiol (CBD) following two local injections.

InnoCan believes the result is encouraging given the 24-hour CBD presence in the bloodstream when administered through traditional channels.

Dr. Ahuva Cern – a senior researcher in the lab of Professor Chezy Berenholz – led the study based on InnoCan’s licensed Liposome Platform Technology for injectable CBD solutions.

The company is involved in a worldwide exclusive research and license agreement with Yissum Research and Development Company, the commercial arm of The Hebrew University of Jerusalem, with the goal of designing, preparing, characterizing and evaluating hydrogels containing CBD (or other cannabinoid) loaded liposomes.

InnoCan’s Liposome Platform Technology may have a wide range of applications, such as epilepsy, pain relief, inflammation and central nervous system disorders.

“We are extremely satisfied with the initial results of this study which shows significant improvement in administrating CBD through InnoCan’s LPT,” said Professor Berenholz. “Finding remaining CBD in the injection site could indicate even a longer prolonged release of CBD into the bloodstream.”

Iris Bincovich, InnoCan’s CEO, added,

“This study marks another positive and exciting result in our ongoing injectable-CBD research. These results may open the door to a wide range of exciting therapeutic possibilities, especially in treatment of conditions related to the central nervous system.”

InnoCan Pharma is a pharmaceutical tech company focused on the development of drug delivery platforms containing CBD.

InnoCan Pharma (INNO) is trading flat at $0.50 per share as of 9:42 am ET.

More From The Market Herald
High Tide - CEO, Raj Grover.

" High Tide’s (TSXV:HITI) Cabana Club loyalty program surpasses 500,000 members

High Tide’s (HITI) Cabana Club loyalty program has now amassed over 515,000 members.

" Hemostemix (TSXV:HEM) announces non-brokered private placement

Hemostemix (HEM) has announced a non-brokered private placement of up to 15 million units.
WELL Health - Chairman & CEO Hamed Shahbazi

" WELL Health (TSX:WELL) closes $34.5M public offering

WELL Health Technologies Corp. (WELL) has completed a bought deal public offering for proceeds of $34.5 million.